Sale

Liver Cancer Therapeutics Market

Global Liver Cancer Therapeutics Market Share, Size, Trends, Growth, Analysis, Forecast: By Cancer Type: Hepatocellular Carcinoma, Cholangio Carcinoma, Hepatoblastoma, Others; By Therapy Type: Ablation Therapy, Others; By Route of Administration; By Distribution Channel; By End User; Regional Analysis; Supplier Landscape; 2024-2032

Global Liver Cancer Therapeutics Market Outlook

The global liver cancer therapeutics market size attained a value of USD 2.50 billion in 2023, driven by the rising prevalence of liver cancer and the growing demand for effective treatment options across the globe. The market is anticipated to grow at a CAGR of 19.85% during the forecast period of 2024-2032 to reach a value of USD 12.78 billion by 2032.

 

liver cancer therapeutics market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Global Liver Cancer Therapeutics Market Trends

Cancer is a life-threatening disease where the cells of a part of our body go out of control and starts growing rapidly. This disease, when effects and starts growing in the liver, is known as liver cancer or hepatic cancer. Although early signs of liver cancer are usually non-existent, they may include unconditional weight loss, appetite loss, upper abdominal pain, nausea, and vomiting, abdominal swelling, jaundice, general weakness and fatigue.

 

  • The rising prevalence of liver cancer diseases is a major factor propelling market growth. People around the world are increasingly adopting a sedentary and unhealthy lifestyle, with increased consumption of alcohol and tobacco. These are very injurious for the liver and are the primary factor to aid liver cancer therapeutics market development.
  • Market players are developing a sturdy drug pipeline that can aid cancer research and development. This will help in the development of new treatments with combination therapy that can provide enhanced treatment to the patients.
  • Market players and institutions are increasingly engaging in research and development activities to develop novel medicines and improve the treatment of cancer through therapeutic drugs, which can extend the patients' lifespan. The availability of improved therapeutic options can significantly help in market expansion.

 

Global Liver Cancer Therapeutics Market Analysis

 

liver cancer therapeutics market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Based on type, the market can be segmented into hepatocellular carcinoma, cholangio carcinoma, and hepatoblastoma, among others. Based on the therapy types, it can be bifurcated into ablation therapy, embolization therapy, radiation therapy, targeted therapy, immunotherapy, and chemotherapy. Based on the route of administration, the market for therapeutics includes oral and intravenous administration. 

 

Based on distribution channels, the market for cancer therapeutics can be segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The regional markets for the liver cancer therapeutics market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. 

 

The comprehensive EMR report provides an in-depth assessment of the market based on Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global market, covering their competitive landscape and the latest developments like mergers, acquisitions, investments and expansion plans. 

 

  • Bayer AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Exelixis, Inc.
  • Merck & Co., Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Others

 

Types of Therapies in the Market for Cancer Treatment

The market for liver cancer therapeutics, based on therapy types, can be divided into ablation therapy, embolization therapy, radiation therapy, targeted therapy, immunotherapy, and chemotherapy.

 

Among the various types of therapies, targeted therapy is expected to cover a major portion of the market owing to the increasing demand for targeted therapy due to its various advantages. Targeted therapies are utilised to directly target tumour cells while eliminating the chances of acquiring side effects on the surrounding normal cells. The increasing utilisation of targeted therapy can be a major driving factor for the segment and market value.

 

Various Routes of Administration for Liver Cancer Therapeutics

Based on the route of administration, the market can be divided into oral and intravenous administration. The intravenous route is the most widely by healthcare professionals as a method of administration for cancer therapy methods such as chemotherapy.

 

Healthcare professionals utilise this route of administration to administer multiple doses of medication or give medicated infusions. This route eliminates the need to inject a needle or tool multiple times to administer the same medicine and allows the medication to directly reach blood circulation.

 

Oral administration is growing in demand due to it being a non-invasive  method of administration. This mode of administration provides multiple benefits including patient comfort, cost-effectiveness, and easy large-scale manufacturing of the medication. The increasing patient preference for oral administration can prople market growth

 

liver cancer therapeutics market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Competitive Landscape

Bayer AG, founded in 1863, and headquartered in Leverkusen, Germany, is a multinational pharmaceutical and biotechnology company. It is one of the world’s largest pharmaceutical companies with a speciality in various fields including pharmaceuticals, agricultural chemicals, seeds and biotechnology products, life sciences, and consumer health. The products developed by the company are applied to tackle some of the biggest challenges including global population growth, an ageing society, and to create sustainability.

 

Pfizer Inc. is an American pharmaceutical and biotechnology company. The company is headquartered in New York, United States, and it has been operating in the industry since 1849. The company works with an aim to introduce treatment solutions in the healthcare sector to create a healthier world. The company has expertise in utilising the science and global resources to improve healthcare around the world. The company is actively providing safe and effective medicines and healthcare services to underserved groups of people.

 

Bristol Myers Squibb Company is a multinational pharmaceutical company, headquartered in New York City, United States. The company was established in the year 1887 and has been operating in the field of biotechnology, pharmaceuticals, healthcare, and research and development, among others, to become one of the leading companies in the world.

 

The company has made multiple advancements in various medical fields such as oncology, haematology, immunology, and cardiovascular disease. Through their diverse array of products and innovative platforms, the company can assist patients in receiving better therapy at any stage of life.

 

Other market players include Exelixis, Inc., Merck & Co., Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd, among others.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Cancer Type
  • Therapy Type
  • Route of Administration
  • Distribution Channels
  • End User
  • Region
Breakup by Cancer Type
  • Hepatocellular Carcinoma
  • Cholangio Carcinoma
  • Hepatoblastoma
  • Others
Breakup by Therapy Type
  • Ablation Therapy
  • Embolization Therapy
  • Radiation Therapy
  • Targeted Therapy
  • Immunotherapy
  • Chemotherapy
Breakup by Route of Administration
  • Oral
  • Intravenous
Breakup by Distribution Channels
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
Breakup by End User
  • Hospitals
  • Clinics
  • Research and Academic Laboratories
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Bristol-Myers Squibb Company
  • Eisai Co.,Ltd.
  • Exelixis Inc
  • Merck & Co. Inc.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc. 
  • Alnylam Pharmaceuticals, Inc. 
  • Onyx Pharmaceuticals, Inc.

 

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Liver Cancer Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Liver Cancer Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Liver Cancer Epidemiology (2016-2031)
    5.3    Europe Liver Cancer Epidemiology (2016-2031)
    5.4    Asia-Pacific Liver Cancer Epidemiology (2016-2031)
    5.5    Latin America Liver Cancer Epidemiology (2016-2031)
    5.6    Middle East & Africa Liver Cancer Epidemiology (2016-2031)
6    Global Liver Cancer Therapeutics Market Overview 
    6.1    Global Liver Cancer Therapeutics Market Historical Value (2017-2023) 
    6.2    Global Liver Cancer Therapeutics Market Forecast Value (2024-2032)
7    Global Liver Cancer Therapeutics Market Landscape
    7.1    Liver Cancer Therapeutics: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Liver Cancer Therapeutics: Product Landscape
        7.2.1    Analysis by Cancer Type
        7.2.2    Analysis by Therapy Type
        7.2.3    Analysis by Route of Administration 
        7.2.4    Analysis by Distribution Channel
        7.2.5    Analysis by End User
8    Liver Cancer Therapeutics Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Liver Cancer Therapeutics Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Liver Cancer Therapeutics Market Segmentation
    11.1    Global Liver Cancer Therapeutics Market by Cancer Type
        11.1.1    Market Overview
        11.1.2    Hepatocellular Carcinoma
        11.1.3    Cholangio Carcinoma
        11.1.4    Hepatoblastoma
        11.1.5    Others
    11.2    Global Liver Cancer Therapeutics Market by Therapy Type
        11.2.1    Market Overview
        11.2.2    Ablation Therapy
        11.2.3    Embolization Therapy
        11.2.4    Radiation Therapy
        11.2.5    Targeted Therapy
        11.2.6    Immunotherapy
        11.2.7    Chemotherapy
    11.3    Global Liver Cancer Therapeutics Market by Route of Administration
        11.3.1    Market Overview
        11.3.2    Oral
        11.3.3    Intravenous
    11.4    Global Liver Cancer Therapeutics Market by Distribution Channel    
        11.4.1    Market Overview
        11.4.2    Hospital Pharmacies
        11.4.3    Retail Pharmacies
        11.4.4    Online Pharmacies
    11.5    Global Liver Cancer Therapeutics Market by End User
        11.5.1    Market Overview
        11.5.2    Hospitals
        11.5.3    Clinics
        11.5.4    Research and Academic Laboratories
        11.5.5    Others
    11.6    Global Liver Cancer Therapeutics Market by Region
        11.6.1    Market Overview
        11.6.2    North America
        11.6.3    Europe 
        11.6.4    Asia Pacific
        11.6.5    Latin America
        11.6.6    Middle East and Africa
12    North America Liver Cancer Therapeutics Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Liver Cancer Therapeutics Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Liver Cancer Therapeutics Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Liver Cancer Therapeutics Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Liver Cancer Therapeutics Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Bristol-Myers Squibb Company
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Eisai Co.,Ltd.
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Exelixis Inc
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Merck & Co. Inc.
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Bayer AG
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Eli Lilly and Company
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    F. Hoffmann-La Roche Ltd
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Pfizer Inc. 
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Alnylam Pharmaceuticals, Inc. 
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Onyx Pharmaceuticals, Inc.
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
24    Liver Cancer Therapeutics - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket


*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market is expected to grow at a CAGR of 19.85% during the forecast period of 2024-2032.

The market is driven by the growing prevalence of liver cancer among people, especially the ageing population, around the world and the simultaneously rising demand for cancer therapeutics.

The increasing investment by market players and the government to introduce innovative solutions in the market and the rising demand for targeted therapy for cancer treatment can aid the market development.

The regional markets include North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

The types of liver cancers found in people include hepatocellular carcinoma, cholangio carcinoma, and hepatoblastoma, among others.

The market provides various therapy types including ablation therapy, embolization therapy, radiation therapy, targeted therapy, immunotherapy, and chemotherapy.

The different services available in the market include oral and intravenous administration.

The different distribution channels available in the market include hospital pharmacies, retail pharmacies, and online pharmacies.

The key players in the market include Bayer AG, Bristol-Myers Squibb Company, Pfizer Inc., Exelixis, Inc., Merck & Co., Inc., Eli Lilly and Company, and F. Hoffmann-La Roche Ltd, among others.

Purchase Full Report

Mini Report

$ 2969     $2699
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5499     $4999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 6599     $5999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 7699     $6999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER